A phase 1, open-label, pharmacokinetic study of TS-172 in patients on hemodialysis
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
7
oral administration of TS-172 20 mg
Taisho Pharmaceutical Co., Ltd selected site
Tokyo, Japan
Concentration of unchanged form in plasma
Time frame: Day 1, 2, 8 and 9
Concentration of major metabolites in plasma
Time frame: Day 1, 2, 8 and 9
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.